A study found that a high percentage of the drugs that the FDA approves expeditiously against the disease, still do not have confirmatory results years later. The program was created in 1992 to accelerate access to HIV drugs.
Today, 85% of accelerated approvals are for anti-cancer drugs. Between 2013 and 2017, there were 46 cancer drugs that were granted accelerated approval. Of those, 63% were converted to regular approval even though only 43% demonstrated clinical benefit in confirmatory trials, the study found.